SNCA
NASDAQSeneca Biopharma, Inc.
News25/Ratings0
Latest news
25 items- INSIDERSEC Form 4 filed by Williams Donald Allen4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 4: Trenschel Robert J. was granted 304,479 units of Common Stock4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 4 filed by Neal James R4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 4: Hallam Thomas was granted 1,592 units of Common Stock4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 4: Finley John David was granted 28,718 units of Common Stock4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 4 filed by Diaz Stephanie4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 4 filed by Dawson Michael John4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 3 filed by Williams Donald Allen3 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 3 filed by Trenschel Robert J.3 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 3 filed by Neal James R3 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 3 filed by Hallam Thomas3 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 3 filed by Finley John David3 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 3 filed by Diaz Stephanie3 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 3 filed by Dawson Michael John3 - PALISADE BIO, INC. (0001357459) (Issuer)
- SECSeneca Biopharma, Inc. filed SEC Form 8-K: Other Events (Amendment)8-K/A - PALISADE BIO, INC. (0001357459) (Filer)
- SECSeneca Biopharma, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - PALISADE BIO, INC. (0001357459) (Filer)
- SECSeneca Biopharma, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - PALISADE BIO, INC. (0001357459) (Filer)
- INSIDERSEC Form 4 filed by Mazzo David J4 - Seneca Biopharma, Inc. (0001357459) (Issuer)
- INSIDERSEC Form 4 filed by GRAY MARY ANN4 - Seneca Biopharma, Inc. (0001357459) (Issuer)
- INSIDERSEC Form 4 filed by Csimma Cristina4 - Seneca Biopharma, Inc. (0001357459) (Issuer)
- INSIDERSEC Form 4 filed by Wei Binxian4 - Seneca Biopharma, Inc. (0001357459) (Issuer)
- PRSeneca Biopharma Announces Successful Approval of Merger with Leading Biosciences, Inc.GERMANTOWN, Md., April 26, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (NASDAQ:SNCA) ("Seneca" or the "Company"), disclosed on April 23, 2021, the passing of the final proposal required for approval of the proposed merger between Seneca and Leading Biosciences, Inc. ("LBS"). The Merger is expected to close on or about April 27, 2021 and the new combined company, Palisades Bio, is expected to begin trading on the Nasdaq Capital Market on or about April 28, 2021 under the ticker "PALI". Seneca and LBS will announce the final exchange ratio prior to the common stock commencing trading on or about Wednesday, April 28, 2021. About Leading BioSciences, Inc.LBS is developing novel therapeutics des
- SECSeneca Biopharma, Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders (Amendment)8-K/A - Seneca Biopharma, Inc. (0001357459) (Filer)
- SECSEC Form 425 filed by Seneca Biopharma, Inc.425 - Seneca Biopharma, Inc. (0001357459) (Subject)
- PRLeading BioSciences Announces Early Efficacy Signal in Reducing Post-Surgical Adhesions in Open Label StudyCARLSBAD, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. ("LBS" or "the Company"), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc. (NASDAQ:SNCA), subject to certain conditions to be completed, to form Palisade Bio, Inc., announced data from an open label GI surgery study with lead asset LB1148 that provided an early indication of efficacy signal in reducing post-surgical adhesions following elective bowel resection. No abdominal adhesions were observed at the time of a follow-up surgery in two patients treated with LB1148. Although these are early data in a limited number of patients, the dat
SNCA FAQ
5 questionsWhere does SNCA stock trade?
Seneca Biopharma, Inc. (SNCA) is listed on NASDAQ.What sector and industry is SNCA in?
Seneca Biopharma, Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Seneca Biopharma, Inc. go public?
Seneca Biopharma, Inc. (SNCA) completed its IPO in n/a.What companies are similar to SNCA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), BIIB (Biogen Inc.), RVMD (Revolution Medicines Inc.). Compare SNCA side-by-side with any of them on Quantisnow.How can I track SNCA on Quantisnow?
Quantisnow aggregates Seneca Biopharma, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNCA to receive live email and push alerts on every new disclosure.